Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Biotechnology

Healthcare
$3.99 +1.53%

+$0.10 today

Market cap
$1.30B
Beta
1.18
P/E (TTM)
-17.7
EPS (TTM)
-$0.35
52W Low $2.25High $7.30

Volume 3.38M

Average 2.73M

TSHA Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Taysha Gene Therapies, Inc.NASDAQ: TSHA

Retained Earnings · Q2 FY2026 · quarter ended Jun 2026

Retained earnings remains negative

Q2 FY2026 retained earnings was -$800.35M, compared with -$650.72M a year earlier.

Context

  • Retained earnings amounted to 170.1% of total assets at the end of Q2 FY2026, down 25.1 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -23.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$800.35M-6.2% QoQ
Last fiscal yearDec 2025
-$711.3M-18.1% YoY
Year agoJun 2025
-$650.72M-23.0% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.0%——
1 year-18.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(711.3M) USD
Year-over-year change
-18.1%

Retained Earnings vs competitors

How TSHA compares with its peers on the latest reported figures

  • TSHA's Jun 2026 retained earnings of -$800.35M is the 6th highest of the 9 companies compared; the peer median is -$772.11M.
  • Its year-over-year change of -23.0% is the 4th highest of 9, against a peer median of -24.4%.
  • Retained earnings amounts to 170.1% of total assets for TSHA, versus a peer median of 184.6%.
TSHA Competitors Peer median
Retained Earnings for TSHA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BNTCBenitec Biopharma Inc.Mar 2026-$260.91M -23.1%—139.5%
NGNENeurogene Inc.Mar 2026-$383.58M -34.6%—145.8%
VYGRVoyager Therapeutics, Inc.Mar 2026-$473.84M -32.7%—216.0%
ABEOAbeona Therapeutics Inc.Mar 2026-$759.15M +8.0%—382.5%
FDMT4D Molecular Therapeutics, Inc.Mar 2026-$785.06M -25.8%—153.1%
TSHATaysha Gene Therapies, Inc.Jun 2026-$800.35M -23.0%—170.1%
RGNXREGENXBIO Inc.Mar 2026-$1.22B -31.3%—355.7%
RCKTRocket Pharmaceuticals, Inc.Mar 2026-$1.49B -16.4%—521.7%
SRPTSarepta Therapeutics, Inc.Mar 2026-$4.55B +2.4%—143.0%
Peer median (excluding TSHA) -$772.11M-24.4%—184.6%

Competitors are the stored peer set for TSHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents149.1M87.88M143.94M139.04M319.77M
Short-term Investments00000
Net Receivables00000
Inventory00000
Other Current Assets6.63M1.19M3.42M892K1.45M
Total Current Assets159.6M96.42M149.87M142.13M324.65M
Property, Plant & Equipment (Net)50.61M25.91M20.41M15.87M16.18M
Goodwill00000
Intangible Assets00000
Long-term Investments2.64M0002.32M
Tax Assets00000
Other Non-current Assets1.11M3.95M2.46M2.37M183K
Total Non-current Assets54.35M29.86M22.86M18.23M18.67M
Total Assets213.96M126.28M172.73M160.36M343.32M
Account Payables21.76M10.95M6.37M3.59M6.28M
Short-term Debt00000
Tax Payables00000
Deferred Revenue033.56M18.11M9.77M0
Other Current Liabilities4.14M4.63M4.99M6.43M10.85M
Total Current Liabilities51.75M62.79M36.76M26.23M26.55M
Long-term Debt37.19M37.97M40.51M43.94M18.17M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities3.74M4.13M1.58M1.31M51.66M
Total Non-current Liabilities66.83M62.54M61.04M62.61M69.83M
Total Liabilities118.57M125.33M97.79M88.84M96.38M
Common Stock01K2K2K3K
Retained Earnings(235.65M)(401.44M)(513.01M)(602.31M)(711.3M)
Accumulated OCI000(4.03M)(192K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity95.38M949K74.94M71.53M246.94M
Total Debt63.09M59.93M61.11M63.18M18.17M
Net Debt(86.01M)(27.95M)(82.83M)(75.86M)(301.6M)

Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Intrinsic Alpha fair value

Locked

Current Price

$3.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.